mTOR-inhibitors (mTORi) have emerged as the cornerstone of TSC treatment, proving effective in the management of severe manifestations including subependymal giant cell astrocytomas (SEGAs) and kidney angiomyolipomata [3,4,5,6]. Here, MTOR is linked to tuberous sclerosis.